GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...
GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
13d
Zacks.com on MSNGSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term OutlookGSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics sold by majority-owned joint venture ViiV Healthcare, which helped group ...
Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an ...
GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...
Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...
GSK's Jemperli has also received expanded approval from the European Commission for certain endometrial cancer cases. In acquisition news, GSK plans to acquire Boston-based biopharmaceutical firm ...
The EMA’s acceptance of the prefilled syringe follows the European Commission’s (EC) approval of GSK’s Jemperli, combined with chemotherapy for the treatment of advanced or recurrent endometrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results